Tris Pharma announced the appointment of Thomas Curatolo as chief commercial officer to lead Tris’ expanded Attention Deficit Hyperactivity Disorder (ADHD) portfolio.  Mr. Curatolo has more than 20 years of commercial brand leadership experience with large, medium and start-up pharmaceutical companies. During his career, he has held positions of increasing responsibility in sales, marketing, strategy and sales operations. He has spent most of the last 2 decades working on or leading...